

Financial Tear Sheet

Corporate Profile

Altimmune is a clinical stage immunotherapeutic biotechnology company located in Montgomery County, MD with additional operating sites in London, UK and Strasbourg, France. By leveraging the complementary attributes of its two innovative vaccine delivery platforms, RespirVec™ and Densigen™, Altimmune is able to design and develop immunotherapeutic products tailored to address a wide range of disease indications including acute respiratory infections, chronic viral infections and cancer, with the potential for fundamental advantages over competing products.

Corporate Profile


ALT (COMMON STOCK)

\$2.04

Change (%) ▼ 0.13 (5.99%)

Volume 24,983

Data as of 08/17/17 1:01 p.m. ET
 Data provided by Nasdaq. Minimum 15 minutes delay
[Refresh quote](#)



Recent Press Releases

August 17, 2017

[ALTIMMUNE ANNOUNCES \\$14.7 MILLION SERIES B PREFERRED STOCK OFFERING](#)

August 10, 2017

[ALTIMMUNE ANNOUNCES SECOND QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE](#)

July 31, 2017

[ALTIMMUNE TO ANNOUNCE SECOND QUARTER 2017 FINANCIAL RESULTS ON AUGUST 10](#)

Upcoming Events



August 10, 2017 8:30 a.m. ET

[SECOND QUARTER 2017 EARNINGS CONFERENCE CALL](#)



June 19, 2017 through June 20, 2017

[ALTIMMUNE, INC. AT THE BIO INTERNATIONAL CONVENTION](#)

Sec Filings

Filing Date	Form	Description	Filing Group
08/17/17	8-K	Report of unscheduled material events or corporate event	Current Reports
08/17/17	8-K	Report of unscheduled material events or corporate event	Current Reports
08/14/17	10-Q	Quarterly report which provides a continuing view of a company's financial position	Quarterly Filings
08/10/17	NT 10-Q	Notification that form type 10-Q will be submitted late	Quarterly Filings
08/10/17	8-K	Report of unscheduled material events or corporate event	Current

		event	Reports
07/20/17	8-K/A	Amendment to a previously filed 8-K	Current Reports
06/27/17	8-K	Report of unscheduled material events or corporate event	Current Reports
06/09/17	8-K	Report of unscheduled material events or corporate event	Current Reports
06/08/17	4	Statement of changes in beneficial ownership of securities	3,4,5
06/06/17	4	Statement of changes in beneficial ownership of securities	3,4,5

Primary IR Contact

Matthew Duffy

Phone: (212) 915-0685

E-mail: matthew@lifesciadvisors.com